San Diego, CA, May 6, 2002 — Structural Bioinformatics, Inc. (SBI) President and COO David D. Muth announced today that Robert Ingersoll has joined the company as Senior Director, National Sales. Mr. Ingersoll’s responsibilities will include planning and management of SBI’s U.S. sales force, and will report directly to David Muth.

“SBI is an exciting drug discovery company which utilizes world leading computational proteomics to accelerate and optimize the drug discovery process,” said Robert Ingersoll. “I am pleased to join SBI at this exciting time of its history.”

“Mr. Ingersoll brings an impressive track record of success in sales and sales management, which will help SBI realize the enormous potential of its Genes to Leads® drug discovery service,” said Mr. Muth. “I am delighted that Bob has joined the SBI management team.”

Mr. Ingersoll has spent the last twelve years with numerous companies within the Johnson and Johnson (J & J) family of companies, including Janssen Pharmaceutica and Ortho Dermatological, a division of Ortho Pharmaceuticals. His career has been built upon increasing responsibility from office-based sales to hospital sales, managed care and sales management. Mr. Ingersoll has achieved numerous awards throughout his career at Johnson and Johnson, including Top Representative in the Los Angeles District, District Representative of the Year, Regional Representative of the Year and Manager of the Year. Under Ingersoll’s direction, his sales teams have consistently ranked among the top in the U.S.

Robert Ingersoll earned a Masters of Business Administration in Management from Pepperdine University in 1994, and his Bachelor of Arts in International Relations from the University of Southern California in 1986. From 1986-90, he was a First Lieutenant in the U.S. Army.

About Structural Bioinformatics, Inc.

Structural Bioinformatics, Inc. (SBI) is a world leader in proteomics-driven drug discovery – the large-scale generation and use of protein structural information to accelerate the drug discovery and optimization processes. SBI’s Genes to Leads® technology offers a practical response to the flood of new drug targets emerging from genomic sequencing efforts for the human genome and the genomes of hundreds of infectious disease agents. SBI’s technology reliably produces drug leads – in 60-120 days – starting with the drug target sequence alone, with an efficiency that is more than 1,000-fold greater than state-of-the-art high-throughput screening. SBI’s proprietary computational proteomics platform produces major benefits in pharmaceutical development, speeding drug discovery, reducing costs and increasing the probability of success.

SBI’s drug discovery pipeline is focused on therapeutics for diabetes, cancer, and inflammatory and infectious diseases. SBI further leverages its technologies to create a growing revenue stream through its StructureBank™ 3-D protein structure database management system, and its structural content products – ProMax™ – a comprehensive drug target database, and Variome™ – individual drug target-specific structural pharmacogenomics database modules.

SBI has partnerships with a number of technology leaders in their respective industry segments, including Johnson & Johnson, Boehringer Ingelheim, Janssen Pharmaceutica, De Novo Pharmaceuticals, DuPont Pharmaceuticals, InCyte Genomics, Inc. and Arqule. SBI’s partners include IBM and Quest Diagnostics – both of whom are part of the company’s premier international investor base.

SBI is headquartered in San Diego CA, with offices in Cambridge MA, Washington DC and Hørsholm, Denmark. More information may be found on SBI’s web site at http://www.strubix.com/.